Cellectis to Present a Development Update for eti-cel at ASH 2025
(Euronext Growth Paris:ALCLS),(NasdaqGM:CLLS), Preliminary data recently shared for eti-cel (UCART20x22) show an 86% ORR and a 57% CR rate (n=7), underscoring its potential to improve outcomes in r/r NHL Preclinical data demonstrated that combining eti-cel with low-dose IL-2 may deepen and extend anti-tumor activity in patients with r/r NHL Eti-cel full Phase 1 dataset, including […]